Personalised mRNA Cancer Vaccines for Dogs: How They Work

When your dog is diagnosed with cancer, the treatment options haven't changed much in decades. Surgery removes the tumour. Chemotherapy kills fast-growing cells. Radiation damages cancer DNA.

None of these treatments are built for your dog's specific tumour. They're one-size-fits-all approaches to a disease that's different in every patient.

Personalised mRNA cancer vaccines work differently. Each vaccine is designed from your dog's individual tumour profile, targeting the specific mutations driving the disease.

This isn't experimental science. It's the same approach currently in Phase III human cancer trials — trials that have shown a 49% reduction in melanoma recurrence risk at five years when combined with immunotherapy.

What makes a cancer vaccine "personalised"

Cancer cells accumulate mutations as they grow. Some of these mutations change the proteins the cell produces. When those mutated proteins are broken down inside the cell, fragments are displayed on the cell surface — like identity badges.

If a fragment is different enough from any normal protein in the body, the immune system can recognise it as foreign and destroy the cell.

These mutation-derived fragments are called neoantigens. They're unique to each tumour. No two dogs' cancers carry the same set of mutations. A Golden Retriever with lymphoma and a Boxer with lymphoma will have completely different mutation profiles.

A personalised mRNA vaccine encodes selected neoantigens into synthetic mRNA. The mRNA is packaged in lipid nanoparticles — the same delivery technology used in billions of COVID-19 vaccines. After injection, your dog's cells take up the nanoparticles, read the mRNA, and produce the neoantigen proteins. The immune system learns to recognise those targets and attacks any cell displaying them.

The existing canine melanoma vaccine, Oncept, targets one fixed protein that's the same for every dog. It's not personalised. A personalised vaccine targets the mutations in your dog's specific tumour.

How the treatment works in practice

The process has four steps:

1. Tumour biopsy and sequencing

Your veterinary oncologist takes a tumour sample (usually during surgery or via needle biopsy) and ships it to a sequencing lab. The lab performs whole-exome sequencing — reading the DNA of both the tumour and a normal tissue sample to identify which mutations are cancer-specific.

2. Neoantigen prediction

A computational analysis predicts which mutations produce the best vaccine targets. The mutations must create peptides that your dog's immune system can recognise. Not every mutation makes a good target. Current prediction methods select 15–34 neoantigens per vaccine.

3. mRNA synthesis and formulation

The selected neoantigens are encoded into a single mRNA sequence. A contract manufacturer synthesises the mRNA and packages it in lipid nanoparticles. The finished vaccine is shipped under cold chain to your vet.

4. Administration

Your vet administers the vaccine as a series of injections, typically over several weeks. The mRNA is transient — it degrades within days and doesn't integrate into your dog's DNA.

What the human data shows

More than 150 human clinical trials of personalised cancer vaccines are underway. The strongest dataset comes from Moderna and Merck's melanoma vaccine, tested in patients whose tumours were surgically removed.

At five years, the vaccinated group had a 49% reduction in risk of recurrence or death compared to immunotherapy alone.

BioNTech tested a personalised vaccine in pancreatic cancer — one of the deadliest cancers, with a 13% five-year survival rate overall. Half of vaccinated patients mounted measurable immune responses. Among responders, only 2 of 8 had relapsed at 3.2 years of follow-up.

The honest framing: these vaccines work best after surgery, when the immune system only needs to find and destroy small amounts of residual disease. In advanced cancer with large tumours, the evidence is weaker. The tumour actively suppresses the immune system, and priming T cells with a vaccine isn't always enough to overcome that.

What's missing from veterinary medicine today

Surgery is still the gold standard for solid tumours in dogs. For cancers like lymphoma, the CHOP chemotherapy protocol achieves remission in 80–90% of patients — but most relapse within a year.

No existing treatment is personalised to your dog's tumour mutations. Chemotherapy kills dividing cells indiscriminately. Targeted therapies like toceranib (Palladia) act on fixed pathways, not individual mutation profiles.

A personalised vaccine fills that gap. It trains the immune system to recognise the exact mutations driving your dog's disease.

What to expect

Novectis Labs is developing personalised mRNA cancer vaccines for dogs through a Founding Patient Programme. This is early access for a limited number of dogs in exchange for contributing anonymised treatment data.

The approach is based on science proven in human trials. It operates under Switzerland's Formula magistralis exemption — the same regulatory pathway that permits compounded medicines prescribed for individual patients.

This is not a proven treatment in dogs yet. There's one documented case — an 8-year-old Staffordshire–Shar Pei cross in Australia whose largest tumour shrank by 75% after receiving a bespoke mRNA vaccine. That's a single case with no control group. It proved the pipeline can be assembled. It didn't prove efficacy.

The human data is compelling. The science is sound. The infrastructure exists — whole-exome sequencing now costs under USD 1,000, and mRNA manufacturing capacity built for COVID vaccines is available across Europe.

What's being built here is the orchestration: sequencing, neoantigen prediction, synthesis, and administration coordinated into a repeatable process for veterinary patients.

Is this right for your dog?

Personalised vaccines are best suited for the post-surgical setting — after the bulk tumour has been removed, reducing the risk of recurrence. Advanced disease with large, immunosuppressive tumours is a weaker indication based on current human trial data.

If your dog has been diagnosed with cancer and you're considering all available options, this is one more tool — one built from proven science, adapted to veterinary medicine for the first time.